Amarantus Bioscience Holdings, Inc. (OTCBB:AMBS) Goes Up On Optimistic News
After a great run in the end of December, Amarantus Bioscience Holdings, Inc. ( OTCBB:AMBS ) entered the new year with some disturbing sessions which cost their stock 25% of the gain they previously made. The company was mentioned in an article on Seeking Alpha on January 2, but we can't say that it was promoting their stock. It was rather a review on the different approaches companies have on the treatment of retinis pigmentosa, an inherited degenerative eye desease which often causes blindness and didn't provide for a change in the direction in which AMBS was moving.[BANNER] Yesteday, however, the company came out with 2 press releases that helped them close the session in the green. AMBS announced a blog post made by their CEO, Mr. Gerald Commissiong on TheChairmansBlog.com which was centered on the progress the company made in 2013 and their plans for an uplisting to a national exchange in 2014. The company also announced that they were going to present at several healthcare conferences next week among which were OneMedForum on Monday, the Biotech Showcase on Wednesday and an investment dinner at the Southern California Investment Forum (SCIF) also on Wednesday. This helped them close the session with a decent 16% gain at $0.075 per share, despite the high volume of traded stock. The massive 10.9 million shares that we saw switch hands in yesterday's session, generated some $760 thousand in dollar volume. Nonetheless, AMBS started today's trading on a bad foot and is already 6% down in the charts with a price of $0.070 per share. Only time will tell if yesterday's gain was just a one day hype result from AMBS's press releases. In any case, be sure to do a lot of due diligence and weigh out the risks if you have any thoughts of betting on AMBS. Growlife, inc. ( OTCBB:PHOT ) also did good in the first sessionof the week and gained a decent 14% in value. US Energy Initiatives Corp. ( OTCMKTS:USEI ) on the other hand had a bad day and lost 23% of its price on high volumes.